All Health and Healthcare Articles
Newest first · Page 153
Pharmaceutical maker Mylan missed analysts' consensus estimate for earnings and revenue. Additional guidance is mixed, causing shares first to fall then to rise. Which direction is more appropriate?
Paul Ausick · 9 years ago
Sarepta Therapeutics saw its shares hit a new multiyear high on Friday after the firm announced that it received a key approval from the FDA.
Chris Lange · 9 years ago
Cancer drug developer ImmunoGen posted sharply lower profits and revenues than analysts were expecting. The stock is taking a beating as a result.
Paul Ausick · 9 years ago
Intellia Therapeutics saw its shares take a dip on Thursday after the firm announced the pricing of its secondary offering.
Chris Lange · 9 years ago
These quarterly numbers are another black eye for Teva Pharmaceutical, sending shares to a low not seen since 2002.
Chris Lange · 9 years ago
Geron is one of the few biopharma winners on Tuesday, with the health care sector in general pushing slightly lower on the day.
Chris Lange · 9 years ago
When Pfizer released its third-quarter earnings report before the markets opened on Tuesday, the results and guidance lived up to what analysts expected but weren't enough to placate investors.
Chris Lange · 9 years ago
In a decisive move, the Neos Therapeutics board of directors unanimously struck down an acquisition proposal from PDL BioPharma.
Chris Lange · 9 years ago
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Chris Lange · 9 years ago
Advanced Accelerator Applications shares made a run early on Monday after it came public that Novartis plans to buy the company.
Chris Lange · 9 years ago
Endo International saw its shares make a solid gain to start off the week after the firm announced preliminary financial results for its third quarter.
Chris Lange · 9 years ago
24/7 Wall St. has collected a few pharma and biotech catalysts that are coming up on the calendar in November and December.
Chris Lange · 9 years ago
Out of all the biotechs that reported earnings last week, Gilead Sciences seems to be the one that hasn’t been taking its medicine in 2017.
Chris Lange · 9 years ago
AbbVie reported better-than-expected third-quarter before the markets opened on Friday due to strong sales of Humira and Imbruvica.
Chris Lange · 9 years ago
Pharma giant Merck reported mixed third-quarter financial results before the markets opened on Friday.
Chris Lange · 9 years ago
More Content
Investing
Lee Jackson · Nov 19, 2026
Investing
Douglas A. McIntyre · Nov 19, 2026
Investing
Omor Ibne Ehsan · Nov 19, 2026